Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

Cancer biology research increasingly recognizes the profound heterogeneity and plasticity of cancer cells. These cells can transition dynamically between ...

Researchers highlighted how an arginine- and proline-restricted diet combined with eflornithine reprogrammed MYCN-driven ...

Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Mineral casts of cancer cell surfaces reprogram fat cells into stem cells and improve insulin sensitivity in obese mice ...

In A Nutshell Scientists reprogrammed skin cells from children with Sanfilippo syndrome into lab-grown brain cells and found ...

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the close of a ...

iACT Stealth is designed to work in tandem with Pluristyx's FailSafe (R) technology. FailSafe's drug-inducible safety feature acts as a genetic "kill switch," allowing for the selective removal of any ...

The FDA granted regenerative medicine advanced therapy designation to RTx-015 for the treatment of retinitis pigmentosa.

HexemBio emerges with a breakthrough blood stem cell rejuvenation technology led by Draper Associates and an advisory ...

HexemBio has launched with a seed round led by Draper Associates to advance a blood stem cell rejuvenation therapy backed by Robert Langer.

iACT Stealth is designed to work in tandem with Pluristyx’s FailSafe® technology. FailSafe’s drug-inducible safety feature acts as a genetic “kill switch," allowing for the selective removal of any ...